Showing 5181-5190 of 8688 results for "".
- Galderma Forms Women In Aesthetics Leadership Councilhttps://practicaldermatology.com/news/galderma-forms-women-in-aesthetics-council/2459928/Galderma Laboratories, L.P. has formed a Women in Aesthetics Leadership Council, comprised of clinicians, clinical trial investigators, CEOs, business owners, and practice managers. "In most industries in the US women hold just 25 percent of senior leadership positions
- RealSelf Survey: 36 Percent of US Adults Are Considering Cosmetic Treatmentshttps://practicaldermatology.com/news/realself-36-percent-of-us-adults-are-considering-cosmetic-treatments/2459933/More than four in five U.S. adults want to improve their personal well-being or appearance in 2019, and 36 percent are considering cosmetic treatments, according to new RealSelf survey. Fully 82 percent of U.S. adults plan to make changes related to their personal well-being and/or appear
- #RealDealAesthetics Takes on Minimally Invasive Body Contouringhttps://practicaldermatology.com/news/realdealaesthetics-takes-on-minimally-invasive-body-contouring/2459934/Save the date: Practical Dermatology®'s sister publication Modern Aesthetics’ newest Tweet chat series -- #RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD is back. The f
- Dermatologists Prescribe the Most Antibiotics, But Usage Is Changinghttps://practicaldermatology.com/news/dermatologists-prescribe-the-most-antibiotics-but-usage-is-changing/2459935/The use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing over time, but there has been an increase in prescriptions associated with dermatologic surgical procedures, a new study finds. The study appears in
- New Review Highlights Comprehensive Treatment Guidelines for Severe ADhttps://practicaldermatology.com/news/new-review-highlights-comprehensive-treatment-guidelines-for-severe-ad/2459936/A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD). The
- Real Housewife Gets Real About Self-Care, Coolsculptinghttps://practicaldermatology.com/news/real-housewife-gets-real-about-self-care-coolsculpting/2459938/Bravo's "The Real Housewives of New York City” Sonja Morgan is the face of Coolscuplting’s new "Let's Get Real About Self-Care" campaign. Morgan joins CoolSculpting in its mission to encourage women across the country by moving self-care to the top of th
- “Outstanding Clearance Rates” for Sebaceous Hyperplasia Facial Lesions Seen with NPShttps://practicaldermatology.com/news/outstanding-clearance-rates-for-sebaceous-hyperplasia-facial-lesions-seen-with-nps/2459943/Pulse Biosciences' Nano-Pulse Stimulation (NPS) technology achieved “outstanding clearance rates” on sebaceous hyperplasia lesions on the face, the company reports. Initial data indicate that 221 of 222 (99.5 percent
- Leadership Changes Announced for Cuterahttps://practicaldermatology.com/news/leadership-changes-announced-for-cutera/2459944/Cutera, Inc.'s James Reinstein resigned as President, Chief Executive Officer, and member of its Board of Directors, effective immediately. The Board has appointed Cutera’s Chief Operating Officer, Jason Richey, as Interim CEO. J. Daniel Plants, Chairman of Cutera, said: &
- “Christmas Berry” Plant Compound Could Fight Uveal Melanomahttps://practicaldermatology.com/news/christmas-berry-plant-compound-could-fight-uveal-melanoma/2459945/A compound extracted from the Christmas berry primrose plant may stops the growth of uveal melanoma, according to preliminary tests. With further testing, the discovery could lead to new therapeutic options for patients with uveal melanoma, report researches from the
- Bristol-Myers Squibb to Acquire Celgenehttps://practicaldermatology.com/news/bristol-myers-squibb-to-acquire-celgene/2459948/Bristol-Myers Squibb Company will acquire Celgene Corp. in a cash and stock transaction with an equity value of approximately $74 billion. The combined company with complementary areas of focus, will opera